Cargando…
Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157334/ https://www.ncbi.nlm.nih.gov/pubmed/35640932 http://dx.doi.org/10.1136/jitc-2022-004699corr1 |
Ejemplares similares
-
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
por: Nguyen, Lee S, et al.
Publicado: (2022) -
Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019) -
Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression
por: Liu, Shiying, et al.
Publicado: (2020) -
Mode-of-action of the PROPELLA concept in fulminant myocarditis
por: Spillmann, Frank, et al.
Publicado: (2019) -
New concepts in fulminant myocarditis and risk of cardiac mortality
por: Ammirati, Enrico, et al.
Publicado: (2017)